短期与慢性疼痛强度与心脏代谢多病进展的关联:多状态马尔可夫模型分析
基于英国生物银行429145名参与者的前瞻性队列,中位随访12.8年,采用多状态模型分析疼痛强度与心脏代谢多病(CMM)进展轨迹的关系。结果显示慢性多部位疼痛和慢性广泛性疼痛增加从初始心脏代谢病(ICMD)向CMM的转换风险,而短期疼痛和慢性单部位疼痛降低ICMD向死亡的转换风险。
要点
- 慢性多部位疼痛和慢性广泛性疼痛增加ICMD向CMM的转换风险。
- 短期疼痛和慢性单部位疼痛降低ICMD向死亡的转换风险。
- 不同疼痛强度对T2D、IHD、HF向CMM转换的影响存在差异。
核心结论
- 慢性疼痛的减轻可能延缓CMM的发生和进展。
研究设计与样本
- 基于英国生物银行的前瞻性队列研究,纳入429145名参与者,中位随访12.8年,使用多状态马尔可夫模型分析。
主要发现
- 随访期间13.1%(56137/429145)发生ICMD,19.6%(10979/56137)进展为CMM,5.3%(22775/429145)死亡。
- 与无痛相比,慢性多部位疼痛(HR 1.11;95%CI 1.06-1.17)和慢性广泛性疼痛(HR 1.26;95%CI 1.13-1.42)增加ICMD向CMM的转换风险。
- 短期疼痛(HR 0.89;95%CI 0.82-0.96)、慢性单部位疼痛(HR 0.88;95%CI 0.82-0.95)和慢性多部位疼痛(HR 0.87;95%CI 0.81-0.93)降低ICMD向死亡的转换风险。
- 短期疼痛还降低从入组向死亡的转换风险(HR 0.94;95%CI 0.89-0.98)。
- 慢性多部位疼痛和慢性广泛性疼痛增加T2D或IHD向CMM的转换风险,仅慢性广泛性疼痛显著增加HF向CMM的转换风险。
临床怎么用
- 对慢性多部位疼痛或广泛性疼痛患者,应加强心脏代谢疾病的监测与管理。
- 短期疼痛和慢性单部位疼痛可能提示较低的死亡风险,但仍需结合临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of pain intensity on the progression trajectories of cardiometabolic multimorbidity (CMM) is not well understood. We attempted to dissect the relationship of short-term pain (STP) and chronic pain intensity with the temporal progression of CMM. METHODS: We conducted a prospective cohort study based on the UK Biobank participants. Incident cases of cardiometabolic diseases (CMDs) were identified based on self-reported information and multiple health-related records in the UK Biobank. CMM was defined as the occurrence of at least 2 CMDs, including heart failure (HF), ischemic heart disease (IHD), stroke, and type 2 diabetes (T2D). The pain intensity was categorized into 5 levels based on pain duration and the number of sites involved, including chronic widespread pain (CWSP), chronic multilocation pain (CMLP), chronic single-location pain (CSLP), STP, and free-of-pain (FOP). Multistate models were used to assess the impact of pain intensity on the CMM trajectories from enrollment to initial cardiometabolic disease (ICMD), subsequently to CMM, and ultimately to death. RESULTS: A total of 429,145 participants were included. Over the course of a 12.8-year median follow-up, 13.1% (56,137/429,145) developed ICMD, 19.6% (10,979/56,137) further progressed to CMM, and a total of 5.3% (22,775/429,145) died. Compared with FOP, CMLP (hazard ratio [HR], 1.11; 95% confidence interval [CI], 1.06-1.17) and CWSP (HR, 1.26; 95% CI, 1.13-1.42) elevated the risk of transitioning from ICMD to CMM. STP (HR, 0.89; 95% CI, 0.82-0.96), CSLP (HR, 0.88; 95% CI, 0.82-0.95), and CMLP (HR, 0.87; 95% CI, 0.81-0.93) lowered the risk of transition from ICMD to mortality, and STP also reduced the risk of transition from enrollment to mortality (HR, 0.94; 95% CI, 0.89-0.98). The results of disease-specific transitions revealed that the influence of pain intensity varied across transitional stages. Specifically, CMLP and CWSP heightened the risk of conversion from T2D or IHD to CMM, whereas only CWSP substantially elevated the transition risk from HF to CMM. CONCLUSIONS: Our results highlighted reductions in chronic pain may mitigate both the onset and progression of CMM, potentially having an important impact on future revisions of cardiometabolic and pain-related guidelines.
引用
- Chen D, Zhang Y, Zhou Y, et al. Association of Short-term Pain and Chronic Pain Intensity With Cardiometabolic Multimorbidity Progression: A Multistate Markov Model Analysis. Anesth Analg. 2025. PMID: 39383101. doi:10.1213/ANE.0000000000007228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。